Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 45.50
Bid: 45.00
Ask: 46.00
Change: -1.00 (-2.15%)
Spread: 1.00 (2.222%)
Open: 46.50
High: 45.50
Low: 45.00
Prev. Close: 46.50
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Avacta Partners With Integumen To Detect Covid-19 In Waste Water

Mon, 13th Jul 2020 11:23

(Alliance News) - Avacta PLC on Monday announced that it has entered into a collaboration with Integumen PLC to evaluate recently generated Affimer reagents that bind the SARS-COV-2 spike protein for the detection of Covid-19 in waste water.

Affimer reagents, a technology developed by drug and diagnostic tool developer Avacta, are a class of non-antibody binding proteins that have been engineered for a wide range of applications where antibodies and aptamers have limitations.

A reagent is a substance used, in this case for detection, for chemical analysis or other reactions.

Testing of the Affimer reagents will take place over the next few weeks after which validation of the sensors will be carried out using real SARS-COV-2 virus samples in a containment level 3 laboratory at the University of Aberdeen.

If these tests go well, it will enable the identification of Covid-19 hotspots in waste-water supplies as the virus can be found in the waste of most Covid-19 patients.

This can provide an early warning system in which authorities can be alerted through Integumen's alert system to prevent the spread of the disease to the wider community.

Avacta Chief Executive Alastair Smith said: "With the spread of Covid-19 continuing to accelerate globally, we are proud to work with partners like Integumen to provide our Affimer reagents for development on a range of platforms to combat the pandemic.

"This collaboration has the potential to deliver a product that will play a crucial role in the early detection of COVID-19 hotspots around the world."

Integumen is a scientific research and AI-as-a-service company focused on production and analysis of bacteria, virus and toxins.

Integumen and Avacta intend to enter a supply agreement for the supply of Affimers into Integumen's sensors upon the successful completion of the tests.

Avacta shares were down 0.2% at 119.25 pence each on Monday morning in London. Integumen shares were up 5.3% at 2.00p each.

Integumen's sensors will then be retrofitted into London-based water supply company Modern Water PLC's Microtox water contamination system units to detect Covid-19 in the water supply.

Modern Water Chief Executive Simon Humphrey said: "We are delighted to be in a position to have a distribution channel that can make the most of the roll-out of the real-time novel sensors for the detection of SARS-CoV-2.

"The completion of this evaluation which, if successful, could identify the level of infection in a community without the need for testing individuals is a very exciting breakthrough and we look forward to working with Integumen to make it happen."

Modern Water shares were up 11% at 2.04p each on Monday morning in London.

By Greg Roxburgh; gregroxburgh@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
15 Dec 2021 08:24

Avacta antigen lateral flow test shown to detect Omicron

(Sharecast News) - Aim-listed Avacta said on Wednesday that its AffiDX® antigen lateral flow test has been shown to detect the Omicron variant of the SARS-CoV-2 virus in clinical samples.

Read more
29 Nov 2021 11:07

IN BRIEF: Avacta gets FDA nod to expand cancer drug trial into US

IN BRIEF: Avacta gets FDA nod to expand cancer drug trial into US

Read more
29 Nov 2021 10:38

FDA gives Avacta the go-ahead for US chemotherapy trials

(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Monday that the US Food and Drug Administration (FDA) has approved its investigational new drug (IND) application for its chemotherapy drug 'AVA6000'.

Read more
2 Nov 2021 11:25

Avacta and Novacyt await UK regulatory approval for Covid-19 tests

Avacta and Novacyt await UK regulatory approval for Covid-19 tests

Read more
2 Nov 2021 10:21

Avacta suspends UK Covid test sales ahead of new approval

(Sharecast News) - Avacta said on Tuesday that it has suspended sales of its AffiDX Covid latest flow rapid antigen tests in the UK while it awaits new approval.

Read more
30 Sep 2021 11:14

Avacta hails "transformative" first half despite widening loss

Avacta hails "transformative" first half despite widening loss

Read more
30 Sep 2021 09:27

Avacta losses widen as development spend increases

(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group reported cash and short-term deposits of £37m at the end of its first half on Thursday, down from £54.5m a year ago and £47.9m at the start of the period.

Read more
29 Sep 2021 10:32

Avacta sees pre-clinical development milestone in LG Chem partnership

Avacta sees pre-clinical development milestone in LG Chem partnership

Read more
29 Sep 2021 09:26

Avacta gets undisclosed milestone payment from LG Chem

(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Wednesday that a preclinical development milestone has been achieved in its multi-target therapeutics partnership with South Korea's LG Chem Life Sciences, triggering an undisclosed milestone payment.

Read more
23 Sep 2021 15:59

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
2 Sep 2021 11:50

IN BRIEF: Avacta hires oncology drug developer as therapeutics CSO

IN BRIEF: Avacta hires oncology drug developer as therapeutics CSO

Read more
18 Aug 2021 14:26

IN BRIEF: Avacta hires cancer doctor Mark Goldberg for board

IN BRIEF: Avacta hires cancer doctor Mark Goldberg for board

Read more
11 Aug 2021 11:29

Avacta doses first patient in chemotherapy medication trial

Avacta doses first patient in chemotherapy medication trial

Read more
11 Aug 2021 10:00

First patient dosed in Avacta's 'AVA6000' trial

(Sharecast News) - Clinical-stage oncology drug company Avacta Group announced on Wednesday that the first patient has been dosed in its phase 1 multicentre trial evaluating 'AVA6000', which it described as a "novel pro-drug" of 'doxorubicin', and its first therapeutic product based on the proprietary 'preCISION' technology.

Read more
4 Aug 2021 17:53

IN BRIEF: Shipment of Avacta's Covid-19 lateral flow test starts

IN BRIEF: Shipment of Avacta's Covid-19 lateral flow test starts

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.